Jun He Law Offices P.C.
Anti-PCSK9 antibodies
The present disclosure provides monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which can block the binding of PCSK9 to low-density lipoprotein (LDL) receptor, and therefore lower the level low-density lipoprotein cholesterol (LDL-C). The antibodies of disclosure provide very potent agents for the treatment of multiple Cardiovascular diseases (CVDs).
WUXI BIOLOGICS IRELAND LIMITED
C A A C C A A C C A A C A C C
C07K A61P A61P C07K C07K A61K A61P C07K C07K A61P A61P C12N A61K C07K C07K
additional inventional inventional additional inventional additional inventional additional additional inventional additional inventional inventional additional additional
Jing Jieying
Li Liu